R374
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 100
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.360
- P53_PATHWAY+0.340
- ANDROGEN_RESPONSE+0.320
- INTERFERON_ALPHA_RESPONSE+0.290
- ADIPOGENESIS+0.280
- MITOTIC_SPINDLE+0.270
- ESTROGEN_RESPONSE_EARLY+0.260
- ANGIOGENESIS+0.230
- INTERFERON_GAMMA_RESPONSE+0.230
- TGF_BETA_SIGNALING+0.230
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.330
- SPERMATOGENESIS-0.260
- KRAS_SIGNALING_DN-0.210
- E2F_TARGETS-0.170
- G2M_CHECKPOINT-0.100
- HEDGEHOG_SIGNALING-0.080
- MYOGENESIS-0.030
- BILE_ACID_METABOLISM-0.020
- ALLOGRAFT_REJECTION-0.010
- HYPOXIA+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CQEETJ66 | Schwannoma | — | 0.826 |
| 2 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.824 |
| 3 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.823 |
| 4 | 0F8847C7-545C-4C3C-B3D0-0681C9480712 | — | — | 0.821 |
| 5 | B5DE434D-6630-4E7E-BA91-6DAC5E2608D3 | — | — | 0.819 |
| 6 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.805 |
| 7 | BS_JK0VPG1T | Schwannoma | — | 0.804 |
| 8 | MNG928 | — | — | 0.798 |
| 9 | 034EEEB2-4BB6-4C72-A63A-C2012C43B4D7 | — | — | 0.794 |
| 10 | SRR934729 | — | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |